Literature DB >> 7683652

The dual mode of inhibition of calmodulin-dependent nitric-oxide synthase by antifungal imidazole agents.

D J Wolff1, G A Datto, R A Samatovicz.   

Abstract

The antifungal imidazoles miconazole, ketoconazole, and clotrimazole inhibit citrulline formation by nitric-oxide synthase. These agents both increase the concentration of calmodulin required to activate the enzyme half-maximally and reduce the maximal velocity of citrulline formation. This inhibition was not reversed by increased concentrations of either the arginine substrate or (6R)-5,6,7,8-tetrahydro-L-biopterin. Miconazole, ketoconazole, and clotrimazole also inhibited the cytochrome-c reductase activity of nitric-oxide synthase competitively versus calmodulin concentration, with apparent Ki (IC50) values of 8, 20, and 0.8 microM, respectively. Miconazole, ketoconazole, and clotrimazole inhibited the activity of calmodulin-dependent cyclic nucleotide phosphodiesterase competitively versus calmodulin concentration, with apparent Ki values of 6, 18, and 25 microM, respectively. These observations are consistent with the proposal that the antifungal imidazoles inhibit citrulline formation by interaction with the nitric-oxide synthase at two sites. Interaction at site 1 reduces the responsiveness of the enzyme to activation by calmodulin, whereas interaction at site 2 (involving putative binding of the imidazole to the heme iron) reduces the maximal velocity of citrulline formation. The interactions of calmodulin antagonists at site 1 occur at substantially lower concentrations of drug than those at site 2 and are the principal determinant of enzyme inhibition.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7683652

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

1.  Functional effects of econazole on inducible nitric oxide synthase: production of a calmodulin-dependent enzyme.

Authors:  R G Bogle; P Vallance
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

Review 2.  Development of nitric oxide synthase inhibitors for neurodegeneration and neuropathic pain.

Authors:  Paramita Mukherjee; Maris A Cinelli; Soosung Kang; Richard B Silverman
Journal:  Chem Soc Rev       Date:  2014-10-07       Impact factor: 54.564

3.  Stress-restress evokes sustained iNOS activity and altered GABA levels and NMDA receptors in rat hippocampus.

Authors:  Brian H Harvey; Frasia Oosthuizen; Linda Brand; Gregers Wegener; Dan J Stein
Journal:  Psychopharmacology (Berl)       Date:  2004-10       Impact factor: 4.530

4.  Ratio of 5,6,7,8-tetrahydrobiopterin to 7,8-dihydrobiopterin in endothelial cells determines glucose-elicited changes in NO vs. superoxide production by eNOS.

Authors:  Mark J Crabtree; Caroline L Smith; George Lam; Michael S Goligorsky; Steven S Gross
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-01-11       Impact factor: 4.733

5.  Effect of anti-fungal imidazoles on mRNA levels and enzyme activity of inducible nitric oxide synthase.

Authors:  R G Bogle; G S Whitley; S C Soo; A P Johnstone; P Vallance
Journal:  Br J Pharmacol       Date:  1994-04       Impact factor: 8.739

6.  Inhibition of NO-medicate responses by 7-ethoxyresorufin, a substrate and competitive inhibitor of cytochrome P450.

Authors:  C G Li; M J Rand
Journal:  Br J Pharmacol       Date:  1996-05       Impact factor: 8.739

7.  Exploring the Role of CYP3A4 Mediated Drug Metabolism in the Pharmacological Modulation of Nitric Oxide Production.

Authors:  José Pérez-Del Palacio; Caridad Díaz; Noemí Vergara; Francesca Algieri; Alba Rodríguez-Nogales; Nuria de Pedro; M Elena Rodríguez-Cabezas; Olga Genilloud; Julio Gálvez; Francisca Vicente
Journal:  Front Pharmacol       Date:  2017-04-12       Impact factor: 5.810

8.  Nitric oxide as inflammatory mediator in post-traumatic stress disorder (PTSD): evidence from an animal model.

Authors:  Frasia Oosthuizen; Gregers Wegener; Brian H Harvey
Journal:  Neuropsychiatr Dis Treat       Date:  2005-06       Impact factor: 2.570

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.